A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

NCT03954834 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults with type 2 diabetes whose blood sugar is not well-controlled by diet and exercise alone.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 478 people

Who can join Ages 18+ · all sexes

Timeline Started 2019-06 · est. completion 2020-10

Where 53 sites · India, Japan, Mexico, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT03954834 ↗

Description as written by the study sponsor.

The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone. The study will last approximately 47 weeks and may include about 15 visits.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03954834 ↗